Gilead-Arcus Partnered Domvanalimab Combo Study Show Improved Progression-Free Survival In Lung Cancer Patients

Gilead Sciences Inc GILD and Arcus Biosciences Inc RCUS announced results from the fourth interim analysis of the ARC-7 Phase 2 study for metastatic non-small cell lung cancer with PD-L1 tumor proportion score ≥50% without epidermal growth factor receptor or anaplastic lymphoma kinase mutations.
The study evaluates the combinations of domvanalimab + zimberelimab (doublet) and domvanalimab + zimberelimab + etrumadenant (triplet) versus zimberelimab monotherapy.
Related: Gilead-Arcus Biosciences Partnered Lung Cancer Therapy Shows Continuous Positive Efficacy Measures.
The doublet and triplet combinations demonstrated clinically meaningful improvements in median progression-free survival (PFS) and six-month landmark PFS rates compared to zimberelimab monotherapy, with a 45% reduction in risk of disease progression or death for the doublet and 35% for the triplet.
Each of the domvanalimab-containing study arms also demonstrated clinically meaningful improvements in objective response rate (ORR) compared to zimberelimab monotherapy. Confirmed ORR was 27%, 41%, and 40% for the zimberelimab monotherapy arm and the domvanalimab-doublet and -triplet arms, respectively.
While the triplet arm did not show an improvement over the doublet arm, it reinforces the results observed in the doublet arm.
The study will continue to monitor PFS and overall survival for the triplet arm as these data mature.
No unexpected safety signals were observed across the three study arms. The domvanalimab-containing study arms were generally well tolerated and showed an overall safety profile.
Price Action: GILD shares are down 5.25% at $81.89, and RCUS shares are down 31% at $21.25 on the last check Tuesday.

Market News and Data brought to you by Benzinga APIs

Comments

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga